https://ground.news/article/alzheon-advances-industry-leading-portfolio-of-oral-anti-amyloid-aggregation-inhibitors-with-first-subject-dosed-in-phase-1-of-alz-507-highlig
Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First...
Apr 8, 2026 - ALZ-507 Designed as Well-Differentiated Oral Candidate Targeting Soluble Amyloid Oligomer Pathology, with Additional Mechanism of Action as APOE4 Corrector...
https://www.biospace.com/alzheon-raises-100-million-series-e-financing-round-to-advance-development-and-commercialization-of-oral-tablet-alz-801-valiltramiprosate-for-treatment-of-alzheimer-s-disease
Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization...
Jun 12, 2024 - Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from...
https://www.biospace.com/alzheon-appoints-b-susan-abushakra-m-d-b-as-chief-medical-officer
Alzheon Appoints Susan Abushakra, M.D., As Chief Medical Officer - BioSpace
chief medical officeralzheonappointssusan
https://www.biospace.com/alzheon-announces-phase-1-results-of-alz-801-a-first-in-class-inhibitor-of-amyloid-formation-and-neurotoxicity-for-alzheimer-s-disease
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And...